Ellipsys Medical files for $10.9M round to expand vascular access tech
What's the deal? Ellipsys Medical has filed a notice with the US Securities and Exchange Commission (SEC) to raise up to $10.9 million in new funding. The filing, made under Regulation D, indicates the company has begun selling securities in the offering.
What's the endgame? Ellipsys Medical develops vascular access technologies for patients with end-stage renal disease. Its flagship product, the Ellipsys System, lets physicians create a percutaneous AV fistula using a single catheter under ultrasound guidance.
Why it matters: The company says the procedure can be performed in multiple care settings and is designed to reduce the need for surgical incisions, implants, and vessel manipulation. Ellipsys works with clinicians and health systems to improve care quality and support long-term access durability.
The signal: A Regulation D filing marks an early, exempt stage of fundraising rather than a completed priced round. For a medtech company targeting dialysis access, the capital points to continued commercialisation of a less invasive alternative to surgical fistula creation.
Read more: intelligence360.news
Image credit: Generated with Gemini
